Private Equity Antitrust: Top Firms in 2026

Key Facts

• PE participants accounted for 2 of every 5 US M&A deals in 2022, up significantly from 2000 levels, making private equity one of the primary subjects of federal antitrust enforcement attention.
• The Hart-Scott-Rodino Act premerger notification threshold stands at $126.4 million. Violations can carry penalties of up to $53,088 per day. The DOJ is seeking over $650 million against KKR in a pending 2025 enforcement action alleging 16 separate violations.
• The FTC's consent order against Welsh Carson Anderson & Stowe, finalized May 2025, established that PE buy-and-build strategies consolidating approximately 43% of Texas hospital anesthesia cases can constitute unlawful monopolization.
• New HSR premerger notification rules, effective February 2025, represent the most significant procedural overhaul in decades. They require expanded disclosure of interlocking directorates, vertical relationships, draft transaction documents, and prior acquisitions going back 10 years.
• At least 15 states have enacted healthcare-specific transaction notification laws, many with no size-of-transaction minimum. Washington and Colorado added general premerger notification laws effective July and August 2025.
• The Trump administration's antitrust leadership has shifted from Biden-era PE-specific hostility to transaction-specific enforcement, while state-level scrutiny is expanding most aggressively on the West Coast and Northeast.

Private Equity Antitrust: The Regulatory Landscape in 2026

The legal framework governing private equity antitrust spans multiple federal statutes and two primary enforcement agencies. An expanding network of state notification regimes adds further complexity. The Hart-Scott-Rodino Act requires parties to notify the FTC and DOJ before closing transactions above $126.4 million. The Clayton Act Section 7 prohibits acquisitions that substantially lessen competition. Section 8 of the same statute prohibits interlocking directorates between competing firms. The Sherman Act reaches coordinated conduct among competing investors, a theory agencies are now applying to institutional investors in the Texas v. BlackRock litigation.

PE sponsors encounter these laws across every major deal structure. Roll-up strategies face cumulative-effects analysis under the 2023 Merger Guidelines, which empower agencies to examine a firm's full acquisition history in any concentrated sector. Leveraged buyouts attract scrutiny when they consolidate fragmented local markets. Minority stakes and growth equity investments now carry disclosure obligations under the new HSR rules. Acquirers must identify board members and officers serving at competing entities. They must also disclose observer rights, most-favored-nation covenants, and information-sharing arrangements indicating influence over a portfolio company.

Federal enforcement is centered in Washington DC, but state-level activity now defines the frontier of PE regulatory risk. Healthcare-specific notification laws cover at least 15 states, many with no transaction-size floor. Texas has been the site of the most prominent PE enforcement action to date. Massachusetts, Oregon, Indiana, and New York have enacted disclosure requirements targeting PE investments in medical practices. Internationally, Australia's mandatory preclosing merger review took effect January 1, 2026. Saudi Arabia and the UAE have significantly strengthened their regimes. Multiple EU member states have adopted discretionary call-in powers for below-threshold serial acquisitions.

PE Antitrust Enforcement: Firm Comparison

The firms below have each shaped the current regulatory compliance landscape through major enforcement actions, consent orders, or active investment in compliance technology. AUM data is unavailable for most firms and has been omitted from the table.

These firms represent the full spectrum of PE antitrust exposure: from landmark enforcement targets setting compliance precedent (KKR, Welsh Carson, Thoma Bravo) to fund managers building businesses in regulatory technology (Accel-KKR, VSS Capital).

Top Picks by Enforcement Significance and Investment Strategy

Defining Roll-Up Enforcement Case: Welsh Carson Anderson & Stowe

The FTC's finalized May 2025 consent order over Welsh Carson's orchestration of U.S. Anesthesia Partners' Texas consolidation is the clearest enforcement blueprint for any PE sponsor pursuing a buy-and-build strategy.

Highest-Stakes HSR Action: KKR & Co.

The DOJ complaint alleges deliberate document alteration before HSR submission in at least 8 deals. This establishes that intentional compliance failures carry disgorgement exposure in addition to civil penalties.

Interlocking Directorate Precedent: Thoma Bravo

The October 2022 DOJ action forced the resignation of all three Thoma Bravo representatives from Solarwinds, along with directors at competitor Dynatrace. This defines the outer limit of permissible PE board representation in overlapping software sectors.

First PE Consent Decree: JAB Consumer Partners

The veterinary services roll-up consent order established that FTC pre-approval of future acquisitions is an available remedy in PE enforcement cases. This provision was subsequently deployed against Welsh Carson and Quantum Energy Partners.

Common Ownership and ESG Frontier: BlackRock, State Street & Vanguard

The FTC and DOJ's joint Statement of Interest in Texas v. BlackRock (filed May 22, 2025) argues that institutional investors coordinating through the NetZero Asset Managers Initiative to reduce coal output can face antitrust liability under both the Clayton Act and Sherman Act. No explicit written agreement is required.

RegTech Investment Leader: Accel-KKR

With $23 billion in cumulative capital commitments and portfolio companies including REG Technologies, Continuity, and INX Software, Accel-KKR is the most active PE investor capturing compliance software demand generated by intensifying antitrust obligations.

Healthcare Regulated Sector Specialist: VSS Capital Partners

The firm's $4 billion strategy targets tech-enabled businesses in healthcare and regulated services. With over 600 acquisitions across 99 platform companies, it demonstrates that disciplined sub-threshold investing can avoid the concentration triggers that drew enforcement against larger healthcare roll-ups.

Top PE Firms in the Antitrust Compliance Landscape

KKR & Co.: The HSR Compliance Cautionary Tale

The DOJ filed the most consequential HSR enforcement action against a fund manager on January 14, 2025, in the Southern District of New York. The complaint alleges KKR failed to submit required Item 4(c) and 4(d) competition-analysis documents in at least 10 deals. KKR also allegedly altered documents after sharing them with officers and directors before HSR submission in at least 8 transactions. In 2 additional deals, the firm allegedly closed without filing notifications at all. The DOJ characterized this pattern as a "culture of noncompliance" threatening the integrity of the premerger review process.

KKR filed a countersuit in the District of Columbia, characterizing the violations as "immaterial" and challenging the DOJ's document collection standards as unconstitutionally vague. For every PE deal team, KKR's case defines the documentation obligations that separate a clean HSR filing from a federal enforcement action.

Welsh Carson Anderson & Stowe: The Roll-Up Enforcement Blueprint

Welsh Carson's healthcare PE strategy became the defining enforcement precedent for buy-and-build antitrust risk across every sector. The firm created U.S. Anesthesia Partners in 2012 and systematically acquired the largest anesthesiology providers in Houston, Dallas, Tyler, Austin, Amarillo, and San Antonio. This achieved approximately 43% of hospital-only anesthesia cases in Texas. The FTC alleged that USAP then used that dominant position to raise prices and enter price-setting agreements with competitors. The agency characterized Welsh Carson as the "mastermind" behind USAP's acquisition strategy.

The FTC's administrative consent order, finalized May 19, 2025, restricts Welsh Carson to a single non-chair board seat at USAP. The order prohibits any increase in ownership or management rights and requires explicit FTC approval before Welsh Carson invests in any anesthesia business anywhere in the United States. FTC Chair Andrew Ferguson, concurring with the order, stated the case was "an ordinary application of the most elementary antitrust principles." This signals that the Trump administration will pursue equivalent cases where concentrated market harm is demonstrable.

Thoma Bravo: The Interlocking Directorate Warning

Thoma Bravo's concentrated software portfolio, spanning cybersecurity, financial technology, and IT operations, made it the primary target when DOJ enforcement of Clayton Act Section 8 intensified in October 2022. The DOJ required the resignation of all three Thoma Bravo director-representatives from Solarwinds Corp, along with four additional directors across four other companies. The agency found that Thoma Bravo board members simultaneously held seats at competing software firms Solarwinds and Dynatrace. Thoma Bravo's subsequent acquisition of identity and access management software company ForgeRock attracted additional scrutiny due to roll-up concentration in that category.

The new HSR rules' interlocking directorate disclosure requirements, effective February 2025, specifically enhanced agencies' capability to detect equivalent situations across all PE portfolios.

JAB Consumer Partners: The First PE Consent Decree

JAB Consumer Partners established the FTC's willingness to require future acquisition pre-approval as a structural remedy in PE roll-up cases. This tool was subsequently applied in the Welsh Carson and Quantum Energy Partners enforcement actions. The consumer brands and veterinary services firm consolidated clinics across multiple markets under two parent companies, then announced an acquisition of a separate veterinary clinic parent company. The FTC's consent order required divestiture of holdings across multiple markets and mandated that JAB obtain FTC pre-approval before any future acquisitions in the veterinary services clinic industry.

General partners managing platform companies in fragmented local services sectors, including dental, dermatology, primary care, and ophthalmology, should treat the JAB case as the baseline enforcement scenario when modeling cumulative concentration risk.

Apollo Global Management: Reading the Enforcement Signal

Apollo's relevance to the current PE antitrust landscape is institutional rather than driven by its own enforcement exposure. In May 2025, the DOJ Antitrust Division hired Bill Rinner, formerly Apollo's senior regulatory counsel, to oversee merger enforcement. Rinner stated publicly that his primary mission is civil enforcement against the "handful of mergers that are problematic, not civil merger deterrence generally," and that there is "no per se rule against mergers or transactions." Many antitrust practitioners interpreted this appointment as confirmation that PE is "no longer in the penalty box" with federal enforcement leadership.

Apollo itself operates across buyout, credit, and real assets strategies. This gives the firm broad exposure across the full range of antitrust risk categories, from HSR compliance to portfolio company competition overlaps in diversified alternatives portfolios.

Accel-KKR: The RegTech Investment Leader

Accel-KKR's $23 billion in cumulative capital commitments make it the best-documented PE investor in regulatory compliance and governance software. The Menlo Park firm's portfolio includes REG Technologies, a compliance and regulatory software platform serving insurance and financial services companies. It also holds Continuity, a regulatory technology platform designed for financial institutions navigating examination and reporting requirements, and INX Software, a compliance and workforce management system.

These investments position Accel-KKR as a direct beneficiary of growing compliance infrastructure demand. Intensifying antitrust obligations, expanded HSR requirements, and state-level healthcare notification laws are all generating this demand across regulated industries. Software founders building compliance platforms can expect Accel-KKR's support to emphasize regulatory domain expertise alongside operational go-to-market scale.

VSS Capital Partners: The Regulated Sector Specialist

VSS Capital Partners applies a disciplined lower mid-market investment thesis to healthcare, business services, and education companies where regulatory complexity creates defensible competitive positions. The firm manages $4 billion in committed capital across 99 platform companies with over 600 cumulative acquisitions, investing $20 to $50 million per transaction. VSS focuses on tech-enabled businesses that must navigate government programs and compliance frameworks as a structural feature of their market.

This approach gives limited partners access to regulated-sector growth equity while keeping individual transactions below the $126.4 million federal HSR threshold. It also keeps the firm largely outside the geographic market concentration thresholds that triggered enforcement against larger healthcare roll-up strategies.

Investment and Enforcement Trends Shaping PE Antitrust Risk

Healthcare Roll-Up Scrutiny Persists Under New Leadership

Healthcare services consolidation remains the highest-risk category for PE antitrust enforcement regardless of administration. FTC Chair Andrew Ferguson explicitly identified healthcare as a priority sector while disavowing general hostility toward PE as a business model. The Welsh Carson final consent order in May 2025, continued FTC litigation against U.S. Anesthesia Partners, and the expansion of state healthcare notification laws to 15 jurisdictions collectively indicate that physician group roll-ups and specialty practice consolidations will face the most sustained regulatory scrutiny of any PE sector throughout 2026.

HSR Compliance Burden Reaches Historic Peak

The February 2025 HSR rules represent the most significant expansion of premerger disclosure obligations since the Act passed in 1976. PE sponsors must now disclose prior acquisitions within 10 years, vertical and supply chain relationships, draft transaction documents showing deal strategy as it evolved, and all interlocking directorates across the fund structure. Antitrust counsel at multiple major law firms have publicly noted that HSR preparation now requires a substantially heavier lift than pre-2025 filings. The KKR enforcement case illustrates the consequences of treating HSR compliance as a routine administrative function rather than a substantive legal obligation with strategic implications.

State Attorneys General Emerge as Independent Enforcement Actors

State-level enforcement is expanding on two parallel tracks. Washington's general premerger notification law took effect July 27, 2025. Colorado's followed on August 6, 2025. Five additional states plus DC have pending legislation to enact equivalent requirements. Healthcare-specific disclosure obligations are proliferating separately, with Massachusetts, Indiana, Oregon, New York, and New Mexico all enacting or strengthening laws in 2025.

For PE sponsors pursuing healthcare investments, state filing requirements can independently delay deal timelines and expose transactions to state attorney general scrutiny. This applies even when federal review terminates quickly or early termination is granted. Transactions well below the $126.4 million federal HSR threshold are fully subject to state healthcare notification laws, most of which contain no size floor.

Common Ownership Theory Extends to ESG Coordination

The FTC and DOJ's joint Statement of Interest in Texas v. BlackRock, filed May 22, 2025, extended antitrust scrutiny to the investment coordination strategies of large institutional investors. The agencies argued that sequential public commitments by BlackRock, State Street, and Vanguard through the NetZero Asset Managers Initiative to reduce coal production output could constitute concerted action under Sherman Act Section 1. No explicit simultaneous agreement is required. For PE general partners, coordinating with co-investors or fund-of-funds LPs on portfolio company operational strategy in concentrated sectors now carries new exposure. ESG-linked coordination provisions in fund documentation and limited partnership agreements warrant antitrust review before execution.

Early Termination Returns With Strategic Trade-offs

Early termination of the 30-day HSR waiting period was reinstated in February 2025 after years of suspension under the Biden administration. Agencies are granting terminations with increasing frequency, reducing closing timelines by several weeks. Requesting early termination triggers immediate public disclosure of the transaction parties and deal details on the FTC's website. This requires PE sponsors and their portfolio companies to be prepared for public announcement on short notice. Federal government shutdown periods interrupted early termination processing in early 2025, adding timing uncertainty that deal teams must factor into closing schedules and financing commitments.

How to Evaluate PE Antitrust Risk

Map the full acquisition history before any new filing. The 2023 Merger Guidelines empower agencies to examine the cumulative competitive effects of a firm's complete acquisition history. This matters most in sectors where consolidation is visible. PE sponsors should audit all prior platform and add-on acquisitions in the target market before submitting HSR filings. Geographic market concentration at the local level deserves particular attention. Welsh Carson's Texas anesthesia case shows that 43% share accumulated through serial acquisitions can be an enforcement trigger. This holds even when individual transactions were cleared at closing.

Audit board appointments across the entire fund portfolio at each new investment. Section 8 of the Clayton Act imposes a strict-liability prohibition. If a PE firm representative serves simultaneously on boards of competing portfolio companies, the interlock is unlawful regardless of intent or commercial rationale. Thoma Bravo's case established that multiple firm representatives holding seats at competing companies compound the violation across the full roster of affected boards. The new HSR rules now require disclosure of interlocking directorates at filing, giving agencies automatic detection capability before an investigation opens.

Engage antitrust counsel at deal origination, not at signing. The Welsh Carson case illustrates that remedy architecture built into an initial consent negotiation is far preferable to litigated enforcement with mandatory divestiture and pre-approval obligations. Early engagement enables deal teams to identify structural remedies before the initial filing. These include divestitures of overlapping assets, board seat limitations, and behavioral commitments. Aligning deal narratives with national priorities recognized by the current administration is a legitimate strategic lever under the Trump administration's enforcement posture.

Extend diligence to state-level notification requirements from the earliest stages. Federal HSR clearance does not terminate state-level review obligations. For any healthcare transaction regardless of size, compliance teams must map exposure across all 15 states with healthcare-specific notification laws before signing. Waiting periods under state laws can extend beyond the federal review calendar. Washington and Colorado's new general notification laws apply to all industries with state nexus. This broadens state filing obligations for mid-market fund managers with portfolio companies in those states.

Which Situation Fits Which Approach?

PE sponsors building healthcare services platforms should treat the Welsh Carson/USAP consent order as their primary compliance benchmark before executing any roll-up strategy. The FTC's order restricts future investments in all hospital-based physician practices nationwide, not just anesthesia. Any specialty consolidation achieving significant local market share faces equivalent scrutiny. Sponsors should model geographic market concentration at the local level before each add-on acquisition. Take particular caution when cumulative share in any service category approaches 30% in a defined market. Firms like VSS Capital Partners concentrate on sub-threshold, regulated-sector businesses with disciplined transaction sizing. They demonstrate one path to accessing healthcare's growth dynamics without the roll-up concentration profile that triggers enforcement.

Technology-focused fund managers assembling software portfolios across overlapping verticals need a systematic board appointment protocol before making each new investment. A Section 8 Clayton Act audit should cross-reference every proposed portfolio company director against the full fund portfolio for competitor overlap. This prevents the enforcement scenario the DOJ executed against Thoma Bravo. Accel-KKR has built a concentrated compliance and governance software portfolio without interlocking directorate enforcement by maintaining disciplined governance structures across its investments.

LPs building diversified alternatives exposure benefit from the current environment's relative clarity. Buyout funds focused on technology, life sciences, and digital infrastructure operate in a more predictable regulatory climate. Healthcare services vehicles face accelerating state attorney general enforcement, independent of federal priorities. Institutional investors coordinating through ESG-linked frameworks should have antitrust counsel review any investment agreement provisions requiring portfolio companies to meet operational targets alongside competing holdings before committing to those terms.

Methodology

This guide to private equity antitrust draws on publicly available enforcement records, agency filings, consent orders, and transaction data from federal courts and regulatory databases. Firm data reflects enforcement actions, consent orders, and investment activity reported through late 2025 and early 2026. Enforcement case details reference official FTC and DOJ filings, including case numbers and docket information where available. State notification law effective dates reflect signed legislation and official agency guidance. Market participation statistics reflect HSR filing data as reported by antitrust practitioners with direct access to filing records. Firms in the profiles and comparison table were selected based on direct relevance to the PE antitrust regulatory compliance landscape, either as enforcement subjects establishing precedent or as active investors in compliance technology sectors. This article does not constitute legal advice; PE sponsors should engage qualified antitrust counsel for transaction-specific guidance.